Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 629 entries
Sorted by: Best Match Show Resources per page
Immuno-modulatory biomaterials as anti-inflammatory therapeutics.

Biochemical pharmacology

Lynch RI, Lavelle EC.
PMID: 34990595
Biochem Pharmacol. 2022 Jan 03;197:114890. doi: 10.1016/j.bcp.2021.114890. Epub 2022 Jan 03.

Biocompatible and biodegradable biomaterials are used extensively in regenerative medicine and serve as a tool for tissue replacement, as a platform for regeneration of injured tissue, and as a vehicle for delivery of drugs. One of the key factors...

Cite
Lynch RI, Lavelle EC. Immuno-modulatory biomaterials as anti-inflammatory therapeutics. Biochem Pharmacol. 2022;197:114890doi: 10.1016/j.bcp.2021.114890.
Lynch, R. I., & Lavelle, E. C. (2022). Immuno-modulatory biomaterials as anti-inflammatory therapeutics. Biochemical pharmacology, 197114890. https://doi.org/10.1016/j.bcp.2021.114890
Lynch, Roisin I, and Lavelle, Ed C. "Immuno-modulatory biomaterials as anti-inflammatory therapeutics." Biochemical pharmacology vol. 197 (2022): 114890. doi: https://doi.org/10.1016/j.bcp.2021.114890
Lynch RI, Lavelle EC. Immuno-modulatory biomaterials as anti-inflammatory therapeutics. Biochem Pharmacol. 2022 Jan 03;197:114890. doi: 10.1016/j.bcp.2021.114890. Epub 2022 Jan 03. PMID: 34990595.
Copy Download .nbib Format: NLM
Per- and polyfluoroalkyl substances target and alter human prostate stem-progenitor cells.

Biochemical pharmacology

Hu WY, Lu R, Hu DP, Imir OB, Zuo Q, Moline D, Afradiasbagharani P, Liu L, Lowe S, Birch L, Griend DJV, Madak-Erdogan Z, Prins GS.
PMID: 34968493
Biochem Pharmacol. 2021 Dec 27;197:114902. doi: 10.1016/j.bcp.2021.114902. Epub 2021 Dec 27.

Per- and polyfluorinated alkyl substances (PFAS) are a large family of widely used synthetic chemicals that are environmentally and biologically persistent and present in most individuals. Chronic PFAS exposure have been linked to increased prostate cancer risk in occupational...

Cite
Hu WY, Lu R, Hu DP, et al. Per- and polyfluoroalkyl substances target and alter human prostate stem-progenitor cells. Biochem Pharmacol. 2021;197:114902doi: 10.1016/j.bcp.2021.114902.
Hu, W. Y., Lu, R., Hu, D. P., Imir, O. B., Zuo, Q., Moline, D., Afradiasbagharani, P., Liu, L., Lowe, S., Birch, L., Griend, D. J. V., Madak-Erdogan, Z., & Prins, G. S. (2021). Per- and polyfluoroalkyl substances target and alter human prostate stem-progenitor cells. Biochemical pharmacology, 197114902. https://doi.org/10.1016/j.bcp.2021.114902
Hu, Wen-Yang, et al. "Per- and polyfluoroalkyl substances target and alter human prostate stem-progenitor cells." Biochemical pharmacology vol. 197 (2021): 114902. doi: https://doi.org/10.1016/j.bcp.2021.114902
Hu WY, Lu R, Hu DP, Imir OB, Zuo Q, Moline D, Afradiasbagharani P, Liu L, Lowe S, Birch L, Griend DJV, Madak-Erdogan Z, Prins GS. Per- and polyfluoroalkyl substances target and alter human prostate stem-progenitor cells. Biochem Pharmacol. 2021 Dec 27;197:114902. doi: 10.1016/j.bcp.2021.114902. Epub 2021 Dec 27. PMID: 34968493.
Copy Download .nbib Format: NLM
DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells.

Biochemical pharmacology

Flat W, Borowski S, Paraschiakos T, Blechner C, Windhorst S.
PMID: 34968485
Biochem Pharmacol. 2021 Dec 27;197:114898. doi: 10.1016/j.bcp.2021.114898. Epub 2021 Dec 27.

The chemotherapeutic agent paclitaxel (PTX) selectively binds to and stabilizes microtubule (MTs). Also, the activated formin Diaphanous Related Formin 1 (DIAPH1) binds to MTs and increases its stability. In a recent study, we found that high DIAPH1 levels correlated...

Cite
Flat W, Borowski S, Paraschiakos T, et al. DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells. Biochem Pharmacol. 2021;197:114898doi: 10.1016/j.bcp.2021.114898.
Flat, W., Borowski, S., Paraschiakos, T., Blechner, C., & Windhorst, S. (2021). DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells. Biochemical pharmacology, 197114898. https://doi.org/10.1016/j.bcp.2021.114898
Flat, Wilhelm, et al. "DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells." Biochemical pharmacology vol. 197 (2021): 114898. doi: https://doi.org/10.1016/j.bcp.2021.114898
Flat W, Borowski S, Paraschiakos T, Blechner C, Windhorst S. DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells. Biochem Pharmacol. 2021 Dec 27;197:114898. doi: 10.1016/j.bcp.2021.114898. Epub 2021 Dec 27. PMID: 34968485.
Copy Download .nbib Format: NLM
Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression.

Biochemical pharmacology

Gong J, Ji Y, Liu X, Zheng Y, Zhen Y.
PMID: 34968486
Biochem Pharmacol. 2021 Dec 27;197:114894. doi: 10.1016/j.bcp.2021.114894. Epub 2021 Dec 27.

Mithramycin A (MIT) has reacquired extensive research attention due to its anti-solid tumor activity and improved pharmacological production. Mechanismly, MIT was broadly used as a c-Myc inhibitor, and c-Myc regulated CD47 and PD-L1 expression which has been demonstrated. However,...

Cite
Gong J, Ji Y, Liu X, et al. Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression. Biochem Pharmacol. 2021;197:114894doi: 10.1016/j.bcp.2021.114894.
Gong, J., Ji, Y., Liu, X., Zheng, Y., & Zhen, Y. (2021). Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression. Biochemical pharmacology, 197114894. https://doi.org/10.1016/j.bcp.2021.114894
Gong, Jianhua, et al. "Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression." Biochemical pharmacology vol. 197 (2021): 114894. doi: https://doi.org/10.1016/j.bcp.2021.114894
Gong J, Ji Y, Liu X, Zheng Y, Zhen Y. Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression. Biochem Pharmacol. 2021 Dec 27;197:114894. doi: 10.1016/j.bcp.2021.114894. Epub 2021 Dec 27. PMID: 34968486.
Copy Download .nbib Format: NLM
Off-target lipid metabolism disruption by the mouse constitutive androstane receptor ligand TCPOBOP in humanized mice.

Biochemical pharmacology

Skoda J, Dohnalova K, Chalupsky K, Stahl A, Templin M, Maixnerova J, Micuda S, Grøntved L, Braeuning A, Pavek P.
PMID: 34971590
Biochem Pharmacol. 2021 Dec 28;197:114905. doi: 10.1016/j.bcp.2021.114905. Epub 2021 Dec 28.

The constitutive androstane receptor (CAR) controls xenobiotic clearance, regulates liver glucose, lipid metabolism, and energy homeostasis. These functions have been mainly discovered using the prototypical mouse-specific CAR ligand TCPOBOP in wild-type or CAR null mice. However, TCPOBOP is reported...

Cite
Skoda J, Dohnalova K, Chalupsky K, et al. Off-target lipid metabolism disruption by the mouse constitutive androstane receptor ligand TCPOBOP in humanized mice. Biochem Pharmacol. 2021;197:114905doi: 10.1016/j.bcp.2021.114905.
Skoda, J., Dohnalova, K., Chalupsky, K., Stahl, A., Templin, M., Maixnerova, J., Micuda, S., Grøntved, L., Braeuning, A., & Pavek, P. (2021). Off-target lipid metabolism disruption by the mouse constitutive androstane receptor ligand TCPOBOP in humanized mice. Biochemical pharmacology, 197114905. https://doi.org/10.1016/j.bcp.2021.114905
Skoda, Josef, et al. "Off-target lipid metabolism disruption by the mouse constitutive androstane receptor ligand TCPOBOP in humanized mice." Biochemical pharmacology vol. 197 (2021): 114905. doi: https://doi.org/10.1016/j.bcp.2021.114905
Skoda J, Dohnalova K, Chalupsky K, Stahl A, Templin M, Maixnerova J, Micuda S, Grøntved L, Braeuning A, Pavek P. Off-target lipid metabolism disruption by the mouse constitutive androstane receptor ligand TCPOBOP in humanized mice. Biochem Pharmacol. 2021 Dec 28;197:114905. doi: 10.1016/j.bcp.2021.114905. Epub 2021 Dec 28. PMID: 34971590.
Copy Download .nbib Format: NLM
Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening.

Reviews of physiology, biochemistry and pharmacology

Farfariello V, Prevarskaya N, Gkika D.
PMID: 32737754
Rev Physiol Biochem Pharmacol. 2021;181:39-56. doi: 10.1007/112_2020_22.

In the last three decades, a growing number of studies have implicated ion channels in all essential processes of prostate carcinogenesis, including cell proliferation, apoptosis, migration, and angiogenesis. The changes in the expression of individual ion channels show a...

Cite
Farfariello V, Prevarskaya N, Gkika D. Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening. Rev Physiol Biochem Pharmacol. 2021;181:39-56doi: 10.1007/112_2020_22.
Farfariello, V., Prevarskaya, N., & Gkika, D. (2021). Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening. Reviews of physiology, biochemistry and pharmacology, 18139-56. https://doi.org/10.1007/112_2020_22
Farfariello, Valerio, et al. "Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening." Reviews of physiology, biochemistry and pharmacology vol. 181 (2021): 39-56. doi: https://doi.org/10.1007/112_2020_22
Farfariello V, Prevarskaya N, Gkika D. Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening. Rev Physiol Biochem Pharmacol. 2021;181:39-56. doi: 10.1007/112_2020_22. PMID: 32737754.
Copy Download .nbib Format: NLM
Ion Channel Dysregulation in Head and Neck Cancers: Perspectives for Clinical Application.

Reviews of physiology, biochemistry and pharmacology

Del-Río-Ibisate N, Granda-Díaz R, Rodrigo JP, Menéndez ST, García-Pedrero JM.
PMID: 32789787
Rev Physiol Biochem Pharmacol. 2021;181:375-427. doi: 10.1007/112_2020_38.

Head and neck cancers are a highly complex and heterogeneous group of malignancies that involve very diverse anatomical structures and distinct aetiological factors, treatments and clinical outcomes. Among them, head and neck squamous cell carcinomas (HNSCC) are predominant and...

Cite
Del-Río-Ibisate N, Granda-Díaz R, Rodrigo JP, et al. Ion Channel Dysregulation in Head and Neck Cancers: Perspectives for Clinical Application. Rev Physiol Biochem Pharmacol. 2021;181:375-427doi: 10.1007/112_2020_38.
Del-Río-Ibisate, N., Granda-Díaz, R., Rodrigo, J. P., Menéndez, S. T., & García-Pedrero, J. M. (2021). Ion Channel Dysregulation in Head and Neck Cancers: Perspectives for Clinical Application. Reviews of physiology, biochemistry and pharmacology, 181375-427. https://doi.org/10.1007/112_2020_38
Del-Río-Ibisate, Nagore, et al. "Ion Channel Dysregulation in Head and Neck Cancers: Perspectives for Clinical Application." Reviews of physiology, biochemistry and pharmacology vol. 181 (2021): 375-427. doi: https://doi.org/10.1007/112_2020_38
Del-Río-Ibisate N, Granda-Díaz R, Rodrigo JP, Menéndez ST, García-Pedrero JM. Ion Channel Dysregulation in Head and Neck Cancers: Perspectives for Clinical Application. Rev Physiol Biochem Pharmacol. 2021;181:375-427. doi: 10.1007/112_2020_38. PMID: 32789787.
Copy Download .nbib Format: NLM
Differential contribution of renal cytochrome P450 enzymes to kidney endothelial dysfunction and vascular oxidative stress in obesity.

Biochemical pharmacology

Muñoz M, López-Oliva E, Pinilla E, Rodríguez C, Martínez MP, Contreras C, Gómez A, Benedito S, Sáenz-Medina J, Rivera L, Prieto D.
PMID: 34822809
Biochem Pharmacol. 2021 Nov 22;195:114850. doi: 10.1016/j.bcp.2021.114850. Epub 2021 Nov 22.

Arachidonic acid (AA)-derived cytochrome P450 (CYP) derivatives, epoxyeicosatrienoic acids (EETs) and 20-hidroxyeicosatetranoic acid (20-HETE), play a key role in kidney tubular and vascular functions and blood pressure. Altered metabolism of CYP epoxygenases and CYP hydroxylases has differentially been involved...

Cite
Muñoz M, López-Oliva E, Pinilla E, et al. Differential contribution of renal cytochrome P450 enzymes to kidney endothelial dysfunction and vascular oxidative stress in obesity. Biochem Pharmacol. 2021;195:114850doi: 10.1016/j.bcp.2021.114850.
Muñoz, M., López-Oliva, E., Pinilla, E., Rodríguez, C., Martínez, M. P., Contreras, C., Gómez, A., Benedito, S., Sáenz-Medina, J., Rivera, L., & Prieto, D. (2021). Differential contribution of renal cytochrome P450 enzymes to kidney endothelial dysfunction and vascular oxidative stress in obesity. Biochemical pharmacology, 195114850. https://doi.org/10.1016/j.bcp.2021.114850
Muñoz, Mercedes, et al. "Differential contribution of renal cytochrome P450 enzymes to kidney endothelial dysfunction and vascular oxidative stress in obesity." Biochemical pharmacology vol. 195 (2021): 114850. doi: https://doi.org/10.1016/j.bcp.2021.114850
Muñoz M, López-Oliva E, Pinilla E, Rodríguez C, Martínez MP, Contreras C, Gómez A, Benedito S, Sáenz-Medina J, Rivera L, Prieto D. Differential contribution of renal cytochrome P450 enzymes to kidney endothelial dysfunction and vascular oxidative stress in obesity. Biochem Pharmacol. 2021 Nov 22;195:114850. doi: 10.1016/j.bcp.2021.114850. Epub 2021 Nov 22. PMID: 34822809.
Copy Download .nbib Format: NLM
DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells.

Biochemical pharmacology

Flat W, Borowski S, Paraschiakos T, Blechner C, Windhorst S.
PMID: 34968485
Biochem Pharmacol. 2021 Dec 27;197:114898. doi: 10.1016/j.bcp.2021.114898. Epub 2021 Dec 27.

The chemotherapeutic agent paclitaxel (PTX) selectively binds to and stabilizes microtubule (MTs). Also, the activated formin Diaphanous Related Formin 1 (DIAPH1) binds to MTs and increases its stability. In a recent study, we found that high DIAPH1 levels correlated...

Cite
Flat W, Borowski S, Paraschiakos T, et al. DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells. Biochem Pharmacol. 2021;197:114898doi: 10.1016/j.bcp.2021.114898.
Flat, W., Borowski, S., Paraschiakos, T., Blechner, C., & Windhorst, S. (2021). DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells. Biochemical pharmacology, 197114898. https://doi.org/10.1016/j.bcp.2021.114898
Flat, Wilhelm, et al. "DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells." Biochemical pharmacology vol. 197 (2021): 114898. doi: https://doi.org/10.1016/j.bcp.2021.114898
Flat W, Borowski S, Paraschiakos T, Blechner C, Windhorst S. DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells. Biochem Pharmacol. 2021 Dec 27;197:114898. doi: 10.1016/j.bcp.2021.114898. Epub 2021 Dec 27. PMID: 34968485.
Copy Download .nbib Format: NLM
PIWI-interacting RNA-23210 protects against acetaminophen-induced liver injury by targeting HNF1A and HNF4A.

Biochemical pharmacology

Xu L, Chen W, Chen J, Jin Y, Ma W, Qi G, Sun X, Luo J, Li C, Zhao K, Zheng Y, Yu D.
PMID: 34968487
Biochem Pharmacol. 2021 Dec 28;197:114897. doi: 10.1016/j.bcp.2021.114897. Epub 2021 Dec 28.

Acetaminophen (APAP) overdose is one of the leading causes of acute liver failure in the US and other developed countries, the molecular mechanisms of APAP-induced hepatotoxicity remain speculative. PIWI-interacting RNAs (piRNAs), a novel class of small non-coding RNAs, have...

Cite
Xu L, Chen W, Chen J, et al. PIWI-interacting RNA-23210 protects against acetaminophen-induced liver injury by targeting HNF1A and HNF4A. Biochem Pharmacol. 2021;197:114897doi: 10.1016/j.bcp.2021.114897.
Xu, L., Chen, W., Chen, J., Jin, Y., Ma, W., Qi, G., Sun, X., Luo, J., Li, C., Zhao, K., Zheng, Y., & Yu, D. (2021). PIWI-interacting RNA-23210 protects against acetaminophen-induced liver injury by targeting HNF1A and HNF4A. Biochemical pharmacology, 197114897. https://doi.org/10.1016/j.bcp.2021.114897
Xu, Lin, et al. "PIWI-interacting RNA-23210 protects against acetaminophen-induced liver injury by targeting HNF1A and HNF4A." Biochemical pharmacology vol. 197 (2021): 114897. doi: https://doi.org/10.1016/j.bcp.2021.114897
Xu L, Chen W, Chen J, Jin Y, Ma W, Qi G, Sun X, Luo J, Li C, Zhao K, Zheng Y, Yu D. PIWI-interacting RNA-23210 protects against acetaminophen-induced liver injury by targeting HNF1A and HNF4A. Biochem Pharmacol. 2021 Dec 28;197:114897. doi: 10.1016/j.bcp.2021.114897. Epub 2021 Dec 28. PMID: 34968487.
Copy Download .nbib Format: NLM
The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives.

Biochemical pharmacology

Bailly C.
PMID: 34968491
Biochem Pharmacol. 2021 Dec 28;197:114895. doi: 10.1016/j.bcp.2021.114895. Epub 2021 Dec 28.

Amlexanox (AMX) is an azoxanthone drug used for decades for the treatment of mouth aphthous ulcers and now considered for the treatment of diabetes and obesity. The drug is usually viewed as a dual inhibitor of the non-canonical IκB...

Cite
Bailly C. The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives. Biochem Pharmacol. 2021;197:114895doi: 10.1016/j.bcp.2021.114895.
Bailly, C. (2021). The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives. Biochemical pharmacology, 197114895. https://doi.org/10.1016/j.bcp.2021.114895
Bailly, Christian. "The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives." Biochemical pharmacology vol. 197 (2021): 114895. doi: https://doi.org/10.1016/j.bcp.2021.114895
Bailly C. The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives. Biochem Pharmacol. 2021 Dec 28;197:114895. doi: 10.1016/j.bcp.2021.114895. Epub 2021 Dec 28. PMID: 34968491.
Copy Download .nbib Format: NLM
Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy.

Biochemical pharmacology

Cui H, Norrbacka S, Myöhänen TT.
PMID: 34968496
Biochem Pharmacol. 2021 Dec 28;197:114899. doi: 10.1016/j.bcp.2021.114899. Epub 2021 Dec 28.

The accumulation of aggregated α-synuclein (α-syn) has been identified as the primary component of Lewy bodies that are the pathological hallmarks of Parkinson's disease (PD). Several preclinical studies have shown α-syn aggregation, and particularly the intermediates formed during the...

Cite
Cui H, Norrbacka S, Myöhänen TT. Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy. Biochem Pharmacol. 2021;197:114899doi: 10.1016/j.bcp.2021.114899.
Cui, H., Norrbacka, S., & Myöhänen, T. T. (2021). Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy. Biochemical pharmacology, 197114899. https://doi.org/10.1016/j.bcp.2021.114899
Cui, H, et al. "Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy." Biochemical pharmacology vol. 197 (2021): 114899. doi: https://doi.org/10.1016/j.bcp.2021.114899
Cui H, Norrbacka S, Myöhänen TT. Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy. Biochem Pharmacol. 2021 Dec 28;197:114899. doi: 10.1016/j.bcp.2021.114899. Epub 2021 Dec 28. PMID: 34968496.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 629 entries